Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CAMP

CAMP4 Therapeutics Corp

3.16

Jul 24 • 3:59 PM ET +0.15 (4.98%)

3.16

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Micro NASD

Peers: KPTI OABI CNTX HUMA RNA TENX TNXP UNCY WHWK MIST

| Held by: VTI VXF IWM IWO VTWO IWC VTWG GSSC RSSL VTHR

Scroll to Statements

Index	RUT
Market Cap	164.09M
Enterprise Value	66.27M
Income	-86.30M
Sales	3.93M
Book/sh	0.60
Cash/sh	1.92
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	48
IPO	Oct 11, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	41.75
P/B	5.31
P/C	1.64
P/FCF	-
EV/EBITDA	-
EV/Sales	16.86
Quick Ratio	6.15
Current Ratio	6.15
Debt/Eq	0.07
LT Debt/Eq	0.06
Option/Short	No / Yes

EPS (ttm)	-2.27
EPS next Y	-0.73
EPS next Q	-0.21
EPS this Y	69.33%
EPS next Y	9.67%
EPS next 5Y	33.58%
EPS past 3/5Y	-5.31% -
Sales past 3/5Y	- -
EPS Y/Y TTM	12.32%
Sales Y/Y TTM	160.53%
EPS Q/Q	48.70%
Sales Q/Q	50.82%
Earnings	May 07 AMC
EPS/Sales Surpr.	-52.38% 15.86%

Insider Own	48.93%
Insider Trans	0.00%
Inst Own	55.84%
Inst Trans	4.17%
ROA	-102.60%
ROE	-209.28%
ROIC	-264.40%
Gross Margin	55.82%
Oper. Margin	-1322.62%
Profit Margin	-2193.72%
SMA20	-20.88%
SMA50	-23.56%
SMA200	-28.47%
Trades

Shs Outstand	51.93M
Shs Float	26.52M
Short Float	4.94%
Short Ratio	7.07
Short Interest	1.31M
52W High	7.75 -59.23%
52W Low	1.32 139.39%
Volatility	14.28% 10.61%
ATR (14)	0.40
RSI (14)	32.26
Beta	0.37
Rel Volume	0.91
Avg Volume	185.59K
Volume	169,586

Perf Week	-14.82%
Perf Month	-21.59%
Perf Quarter	-28.83%
Perf Half Y	-32.33%
Perf YTD	-48.45%
Perf Year	64.58%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	8.36
Prev Close	3.01
Price	3.16
Change	4.98%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-16-26	Upgrade	JP Morgan	Neutral → Overweight	$9
Jun-10-26	Initiated	Chardan Capital Markets	Buy	$6.50
Apr-14-26	Initiated	Rodman & Renshaw	Buy	$7
Oct-02-25	Initiated	Cantor Fitzgerald	Overweight	$7
Sep-16-25	Downgrade	JP Morgan	Overweight → Neutral
May-27-25	Initiated	Wedbush	Outperform	$8
Nov-05-24	Initiated	William Blair	Outperform
Nov-05-24	Initiated	Piper Sandler	Overweight	$18
Nov-05-24	Initiated	JP Morgan	Overweight	$23

Jul-17-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -10.51%
Jun-19-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-21-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-14-26 07:00AM	CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder (GlobeNewswire)
May-07-26 04:05PM	CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights (GlobeNewswire) +6.90%
08:00AM	Loading…
Apr-28-26 08:00AM	CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation (GlobeNewswire)
Apr-17-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-24-26 07:00AM	CAMP4 Appoints Michael MacLean to its Board of Directors (GlobeNewswire)
Mar-06-26 04:05PM	CAMP4 to Participate in Upcoming Investor Conferences (GlobeNewswire) -8.50% +49.40%
Mar-05-26 04:05PM	CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights (GlobeNewswire) +12.50%
Feb-20-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-16-26 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -21.00%
Jan-13-26 12:00PM	CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why (Zacks)
Jan-06-26 08:00AM	CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 03:22PM	Getty Images, Torm, and More Stocks See Action From Activist Investors (Barrons.com)
06:01AM	Loading…
Dec-19-25 06:01AM	Novo files for CagriSema approval; Merck and Pfizers trial win (BioPharma Dive)
Dec-18-25 07:10AM	CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock (GlobeNewswire) -12.90%
07:00AM	CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries (GlobeNewswire)
Dec-12-25 04:05PM	CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.99%
Nov-14-25 04:05PM	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 04:05PM	CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +6.97%
Oct-14-25 02:09PM	3 Healthcare Companies Insiders Are Buying (MarketBeat) -6.63%
Oct-01-25 08:00AM	CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 (GlobeNewswire)
Sep-25-25 12:00PM	CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's What You Should Know (Zacks) +7.53%
Sep-17-25 09:40AM	Apple initiated, Hershey upgraded: Wall Streets top analyst calls (TipRanks) -6.50%
Sep-16-25 09:35AM	Apple initiated, Hershey upgraded: Wall Street's top analyst calls (The Fly)
Sep-10-25 07:00AM	CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders (GlobeNewswire) +40.20%
Aug-14-25 04:05PM	CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) +6.16% +7.74%
Jun-30-25 08:00AM	Sequans Appoints Jason W. Cohenour to Board of Directors (Newsfile)
May-16-25 06:00AM	CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire) +9.52%
04:05PM	Loading…
May-13-25 04:05PM	CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights (GlobeNewswire) -7.92%
Apr-28-25 04:30PM	CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting (GlobeNewswire) -10.00% -5.15%
Apr-05-25 11:00AM	Markets Watch Out For Core CPI With Big Banks Set To Report Earnings (Seeking Alpha)
Mar-27-25 04:05PM	CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -10.16%
Mar-18-25 08:00AM	CAMP4 Appoints Multiple Industry Veterans to its Board of Directors (GlobeNewswire)
Mar-04-25 05:24AM	CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 2025 (Insider Monkey) -5.27%
Feb-06-25 08:00AM	CAMP4 to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.95%
Jan-13-25 08:00AM	CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 04:05PM	CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones (GlobeNewswire)
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire) -8.08%
Dec-02-24 08:00AM	CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +5.85%
Nov-21-24 04:05PM	CAMP4 Reports Third Quarter 2024 Financial Results (GlobeNewswire) +8.44% -6.40%
Oct-10-24 07:07PM	CAMP4 Announces Pricing of Initial Public Offering (GlobeNewswire)

CAMP4 Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a class of RNA-targeting therapeutics for upregulating gene expression and restoration of healthy protein levels to treat a broad range of genetic diseases. Its lead product candidate is CMP-002. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CEOMr. Joshua Mandel-Brehm

Founder & Independent DirectorDr. Richard A. Young Ph.D.

Chief Financial OfficerMs. Kelly Gold

M.D.Dr. Yuri Maricich M.B.A.

Founder & Chairman of Scientific Advisory BoardDr. Leonard I. Zon M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
5AM Partners VI, LLC	10% Owner	Sep 11 '25	Buy	1.53	2,941,176	4,499,999	2,941,176	Sep 15 08:12 PM
Polaris Management Co. VII, L.	10% Owner	Sep 11 '25	Buy	1.53	1,307,189	1,999,999	2,825,500	Sep 11 04:59 PM
Nashat Amir	Director	Sep 11 '25	Buy	1.53	1,307,189	1,999,999	2,825,500	Sep 11 04:48 PM
Maricich Yuri	Chief Medical Officer	Sep 11 '25	Buy	1.65	6,060	9,999	6,060	Sep 11 04:25 PM
Gold Kelly	Chief Financial Officer	Sep 11 '25	Buy	1.65	6,060	9,999	67,877	Sep 11 04:24 PM
Mandel-Brehm Josh	Chief Executive Officer	Sep 11 '25	Buy	1.65	6,060	9,999	278,417	Sep 11 04:23 PM
Young Richard A	Director	Sep 11 '25	Buy	1.65	15,151	24,999	170,010	Sep 11 04:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAMP

CAMP4 Therapeutics Corp

Upgrade your Finviz experience